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Sm_uary We established an in vitro cytokinesis-block micronucleus assay of human tumours for estimation
of the proportion of cells undergoing mitosis (the dividing fraction, DF), the time for the number of nuclei to
double and the radiosensitivity in terms of the micronucleus frequency, based on a concept described
previously. Under certain conditions, the nuclear number doubling time (NNDT) was considered to represent
the potential doubling time. Tumour specimens obtained at surgery were disaggregated into single-cell
suspensions and were directly cultured in the presence of cytochalasin B with or without irradiation. At
various intervals, the percentage of multinucleate cells (the plateau value represented the DF), the average
number of nuclei per cell and the number of micronuclei in binucleate cells were determined. DF and NNDT
values were obtained in 58 of the 73 tumours investigated, and the micronulceus frequency was obtained in 54
of these 58 tumours. The DF ranged from 4.1% to 71% and the NNDT ranged from 3.1 to 83 days. A DF
>20% was associated with a higher recurrence rate in patients undergoing curative operation. A correlation
was found between the NNDT and the time to relapse in patients with recurrent disease. The average number
of micronuclei per binucleate cell at 2 Gy of irradiation (after subtraction of the value at 0 Gy) ranged from
0.052 to 0.35. Tumours which produced more micronuclei after irradiation showed a better response to
radiotherapy. This assay can be readily performed on human tumours and appears to have promise as a
predictive assay for radiation therapy.
Recently, the importance of an individualised approach to
cancer therapy based on the biological characteristics of each
patient's tumour has been increasingly stressed. In radiation
therapy, the prediction of biological parameters such as the
intrnsic radiosensitivity, proliferative activity (especially the
potential doubling time: Tpo) and degree of hypoxia would
be helpful in planning optimal treatment (Peters et al., 1988).
Several assay systems have been developed to estimate these
parameters (Begg et al., 1988; Peters et al., 1988; Brock et al.,
1989; H6ckel et al., 1993), but newer and better assays are
needed because all of the existing ones have some disadvan-
tages. In addition, none of the assays allows two or more
parameters to be estimated simultaneously.
In our previous studies using xenografted human and
mouse tumours (Shibamoto & Streffer, 1991; Shibamoto et
al., 1991), we developed a new method of estimating tumour
radiosensitivity and proliferative activity, which involved
determining the micronucleus (MN) frequency after irradia-
tion, the fraction of tumour cells undergoing mitosis in vitro
(the dividing fraction, DF) and the presumed time for the
number of tumour cell nuclei to double in vitro (nuclear
number doubling time, NNDT). The NNDT is considered to
be similar to Tpot provided that the culture conditions do not
alter karyokinesis. This method makes use of the cytokinesis-
block MN assay (Fenech & Morley, 1985), in which tumours
are disaggregated into single cells and cultured with or with-
out irradiation for about a week in the presence of
cytochalasin B to block cytoplasmic (but not nuclear)
division. The MN frequency in binucleate cells (BNCs) was
previously found to correlate with the surviving cell fraction
in nine out of ten tumours investigated (Shibamoto et al.,
1991). The maximal percentage of multinucleate cells
(MNCs) (= the DF) was found to correlate with the
bromodeoxyuridine (BrdU) labelling index, and the NNDT
generally corresponded to the Tpot estimated by the BrdU
flow cytometry method (Shibamoto & Streffer, 1991).
As the next step in our studies, we have investigated the
feasibility of performing this assay in various human
tumours. We also investigated the correlation between assay
data and clinical outcome.
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Materals and methods
Tumour specimens
All specimens were obtained at the time of major surgery and
not by biopsy. A total of 73 solid tumours resected from
patients without preoperative irradiation or chemotherapy
were evaluated. Malignant ascites from a patient with pan-
creatic cancer was also investigated, but we could not obtain
a result because of excessive contamination with non-
malignant cells. Since the first aim of this study was to
determine the types of tumours suitable for this assay, a
variety of lesions were studied irrespective of their suitability
for post-operative radiotherapy. The tumours ranged from
50 mg to 4.0 g in weight, with a median weight of 850 mg.
Assai procedure
The method used was similar to that of previous studies
(Shibamoto & Streffer, 1991; Shibamoto et al., 1991) with
slight modifications. The current standard procedure was
performed as follows. Tumour specimens were minced with
scissors and treated at 3TC for 2 h with 1 mg ml-'
collagenase/dispase (Boehringer, Mannheim, Germany) dis-
solved in phosphate-buffered saline. Then the resulting
tumour cell suspension was filtered through a fine wire mesh
and viable cells were counted using trypan blue. The propor-
tion of viable cells ranged from 25% to more than 90%, and
the cell yield ranged between 1 x 106 and 7 x 10' per gram of
tumour tissue. After removing the collagenase/dispase solu-
tion by centrifugation, the cells were plated into multiple
collagen-coated dishes (20cm2, Iwaki Glass, Tokyo). When
the cell yield was sufficient, 3-5 x 105 cells per dish were
plated into up to 25 dishes, but when the yield was lower
fewer cells were plated into a smaller number of dishes. The
culture medium used was Ham F12 supplemented with 20%
fetal bovine serum and 0.2mgml-' gentamicin sulphate.
About I h after plating, 2 and 4 Gy of irradiation was
given to some of the dishes (usually 2-3 dishes per dose),
using either a linear accelerator (10 MV X-ray) or an X-ray
apparatus (250 kVp, 15 mA, 0.5 mm copper filter). These two
types of X-rays have been confirmed to have a similar
biological effect (Shibamoto et al., 1992). Within 2 h of
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platg, cytochalasin B dissolved in dimethylsuiphoxide was
added to all dishes. Various concentrations ofcytochalasin B
(0.5, 1, 1.5, 2, and 3 igml-') were added whenever the cell
yield allowed it, but otherwise the drug was only added at
1.5 Lgml-V'. The medium and cytochalasin B were both
replaced when the culture duration was longer than 1 week.
Fixation andstainng
Cultures were terminated at various intervals and the cells
were fixed with 1% glutaraldehyde in phosphate buffer,
treated with 5 N hydrochloric acid for 20min and stained
with Schiffis reagent for 1 h as described previously
(Shibamoto et al., 1991). When there was a sufficient number
of culture dishes, unirradiated cells were fixed on a daily
basis until day 5 and every other day thereafter until day
9-14. Irradiated cells were usually fixed on days 4-6 for
high-grade tumours and on days 5, 7 and 9 for low-grade
tumours. By monitoring the increase in BNCs in the unir-
radiated dishes, the best day for starting fixation of the
irradiated cells was determined.
moto & Streffer, 1991). The NNDT was estimated by fitting
the initial part of the nuclear ratio curve (i.e. the number of
nuclei per cell) to an exponential curve and extrapolating it
as shown in Figure 2 when necessary. This extrapolation was
necessary for nearly all (52 of 58) tumours in which the
nuclear ratio did not exceed 2.0. For curve fitting, all the
points on the ascending portion were used; the data obtained
on days 1-3 were used in almost all cases, while those
obtained on day 4 or later were also used whenever appropri-
ate. The fitted curve did not extrapolate through the origin in
most cases, because some delay existed before mitosis com-
menced (Shibamoto & Streffer, 1991) and because some
tumours contained naturally mutlinucleate cells (Shibamoto
et al., 1991).
Tlhe assay data for all the tumours are shown in Tables I
and II. The DF ranged from 4.1% to 71% with a median of
21%, and the NNDT ranged from 3.1 to 83 days with a
median of 9.8 days. The average number of micronuclei per
binucleate cell at 2 Gy after subtraction of that at 0 Gy
[MN/BNC (2 Gy-O Gy)] ranged from 0.052 (bladder cancer)
to 0.35 (liver metastasis of pancreatic cancer) with a median
of 0.12.
Scoring andanalysis
Tumour cells were distinguished from normal cells on the
basis of morphological criteria such as nuclear irregularity
and a high nucleocytoplasmic ratio (Papanicolaou, 1954;
Barker & Sanford, 1970), and only those judged to be
tumour cells were scored. The cells with different numbers of
nuclei (mononucleate, binucleate, trinucleate, etc.) and the
micronuclei in the BNCs were counted under a microscope
equipped with a phase-contrast apparatus at a magnification
of 1,000. When the overall cell number was high, at least 500
cells were assessed per dish. At least 50 (usually 100-200)
BNCs were assesse to determine the MN frequency. BNCs
with three or more micronuclei were occasionally found, but
all micronuclei were scored.
Then the percentage of MNC, the average number of
nudei per cell and the average number of micronuclei per
single BNC were calculated. The DF (= maximal MNC
percentage) and NNDT were estimated from the unirradiated
group of cultures as described previously (Shibamoto &
Streffer, 1991) (see also the Results section). For both unir-
radiated and inradiated cells, the MN frequency at the time
ofpeak BNC yield was assumed to be representative for each
culture. The incrase in BNCs appeared to be suppressed and
delayed by irradiation in some tumours, but the day of the
peak BNC yield did not differ between irradiated and unir-
radiated cultures of most tumours.
Result
DF, NNDTand MNfrequency
The DF and NNDT values could be detemined in 58 of the
73 tumours investigated. In the remaining tumours, a low cell
yield (generally because of the small specimen size) and/or
the inability of the cells to become attached to the culture
dishes meant that insufficient cells could be evaluated. The
MN frequency after radiation was evaluable in 54 of the 58
tumours. In the emnaining four it was unevaluable because
there was a low number of BNCs (especially after radiation)
and/or because not only the nuclei and micronucki but also
the cytoplasm were stained, making the micronuclei
unientifiable.
Figures 1 and 2 show assay data for pancreatic and lung
cancer specmens rpively. Data on DF, NNDT and MN
frequency could all be obtaied in a single series of
experiments. The percentage of MNCs also reached a plateau
in all the other tumours after day 5 (i.e. the percentage of
MNCs did not diffe between at kast two consecutive time
points), so that the DF could be determined from the plateau
value. This was also found to be the case in our previous



























Duration of culture (days)
0 2 4
Dose (Gy)
Fwe 1 Assay of a liver metasIS from pancreatic cancer.
Left the percentage of mutlinucleate cells (MNCs) and the
average number of nuclei per cell as a function of culture dura-
tion. An ecponential curve (- - -) was fitted to the five points
obtained on days 1-6. Right: the average number of micronuclei
(MN) per binuceate cell (BNC) as a function of the radiation
dose. The dose-response curve of MN frequency was drawn by
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Fugwe 2 Assay of a pulmonary adenocarinoma. The curve for
the number of nuclei per cell was fitted to the four points
obtained on days 1-4.MICRONUCLEUS ASSAY OF HUMAN TUMOURS 69
Table I Assay data for various types of carcinoma
DF NND7 MN/BNC"
Organa Histology n (%) (days) 0 Gy 2Gy 4 Gy
Lung ADC 9e 25 7.0 0.082 0.21 0.32
(16-42) (4.2-11) ± 0.012 ± 0.07 ±0.09
Lung SCC 4f 31 8.0 0.090 0.31 0.50
(19-53) (4.5-17) ± 0.018 ±0.06 ± 0.10
Lung Small cell CA 1 35 3.1 0.14 0.41 0.64
Lung (brain MET) ADC 2 19 11 0.080 0.26 0.42
(17-21) (11-12) ±0.010 ±0.07 ±0.13
Lung (brain MET) SCC 1 22 7.4 0.088 0.22 0.29
Breast ADC 55 27 8.5 0.11 0.27 0.44
(lung or brain MET) (14-31) (5.0-18) ±0.04 ±0.15 ±0.23
Pancreas ADC 6 49 4.6 0.096 0.26 0.39
(liveror peritoneal (31-71) (3.1-5.1) ±0.016 ±0.10 ±0.14
MET)
Bladder TCC 4 15 18 0.063 0.20 0.32
(12-19) (14-20) ±0.018 ±0.08 ±0.09
Parotid gland ADC (grade I) 1 13 17 0.075 0.20 0.30
Oral floor SCC 1 20 8.8 0.092 0.30 0.44
Hypopharynx SCC 1 28 6.9 0.070 0.22 0.36
Buccal mucosa SCC 1 24 7.2 0.067 - -
Stomach ADC 1 20 11 0.077 0.14 0.21
Kidney Renalcei CA 1 19 11 0.042 0.10 0.15
Rectum ADC 1 25 6.2 0.071 0.16 0.25
"MET,metastasis.bADC,adenocarcinoma; SCC,squamouscellcarcinoma; CA,carcinoma;TCC,transitional
cellcarcinoma. 'DF, dividingfraction; NNDT, nuclearnumberdoublingtime; themedianandrangewereshown
when n>2. 'MN/BNC, mean number ofmicronuclei per binucleatecell; the mean and standard deviation were
shown when n>2. 'n = 8, 'n = 3, 'n = 4, for MN/BNC at 2 and 4 Gy.
Table H Assay data for brain tumours and sarcomas
DP" NND7* MNIBNC
Histologva n (%) (days) 0 Gy 2Gy 4 Gy
(a) Brain twnours
Glioblastoma 3 20 10 0.090 0.26 0.41
(17-26) (8.3-17) ± 0.034 ± 0.09 ± 0.08
Meningioma 4 8.2 53 0.058 0.14 0.21
(4.1-9.5) (35-83) ± 0.023 ± 0.04 ± 0.05
Anaplastic astrocytoma 1 21 8.2 0.088 0.15 0.27
Medulloblastoma 1 34 9.3 0.11 0.34 0.61
Haemangiopericytoma 1 15 17 0.067 0.13 0.15
(grade II-III)
Oligodendroglioma 1 5.8 66 0.067 0.15 0.22
Pituitary adenoma 1 5.9 35 0.055 0.14 0.20
Cerebellar astrocytoma 1 7.5 31 0.051 0.29 0.51
(b) Sarcomas
Osteosarcoma (lung MET) 3 20 12 0.13 0.32 0.42
(13-24) (11-17) ± 0.08 ±0.08 ± 0.08
Chondrosarcoma 1 9.5 22 0.077 - 0.20
Liposarcoma 1 16 12 0.094 0.18 0.25
Alveolar soft-tissue 1 39 4.3 0.069 0.14 0.18
sarcoma (brain MET)
'MET,metastasis.bDF,dividingfraction; NNDT, nuclear numberdoublingtime,the median
and range were shown when n>2. cMN/BNC, mean number ofmicronuclei per binucleate cell,
the mean and standard deviation were shown when n>2.
Influence ofthe cytochalasin B concentration and culture
duration
The influence ofdifferent concentrations ofcytochalasin B on
the MNC yield and MN frequency was tested in seven
tumours. In five of them, a concentration of 0.5 jg mlh ' was
not sufficient to obtain the highest MNC yield, while in four
tumours a concentration of 3 pg m1' produced a lower
MNC percentage than 1, 1.5 or 2pgml-'. Moreover, shrin-
kage of cells and a decrease in the number of attached cells
was observed at a concentration of 3 Lg ml1 l in three
tumours. In contrast, no significant differences were noted
between the concentrations of 1, 1.5 and 2 pg ml1'.
Therefore, 1-2 pgml-' appeared to be the concentration
range yielding the highest MNC percentage, and we used
1.5pgml-' in the subsequent experiments. Variations in the
cytochalasin B concentration had little effect on the MN
frequency in BNCs, although there was a non-signifiant
tendency for the frequency to increase at lower concentra-
tions in two tumours.
Our previous study (Shibamoto et al., 1991) showed that
the MN frequency in BNCs of both irradiated and unir-
radiated cultures inreased as the culture durrtion became
longer in some tumours, but the present study only detected
this phenomenon in two tumours in which cells with three or
more nulcei became prevalent.
Correlation ofthe assay data with the clinical outcome
Of the 58 evaluable patients, 33 underwent macroscopically
curative tumour resection, excluding the patients with distant
metastases. Two of the 17 patients whose tumours had a
DF<20%, and six of the 16 patients whose tumours had a70 Y. SHIBAMOTO et al.
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Fuge 3 Relapse-free survival curves according to the dividing
fraction (DF) for the patients undergoing macroscopically
curative operation. P = 0.00568.
y= -6.0154 + 1.8325x R2 = 0.849
0
0
0 10 20 30 40 50
NNDT (days)
DF .20% received post-operative radiation therapy. Figure
3 shows that a DF .20% was associated with a significantly
higher recurrence rate (P = 0.00568 by the generalised Wil-
coxon test). Six patients developed recurrence, and the inter-
val between the previous surgery and relapse was also known
in the 13 patients operated on for recurrence. Figure 4 shows
a good correlation between the NNDT and the time to
relapse in these 19 patients (R=0.921, P<0.001).
In 17 of the 29 patients who underwent radiation therapy,
the response of the primary or metastatic lesions was
evaluable. Figure 5 shows the correlation between the
tumour response to radiotherapy and the MN frequency
determined at 2 Gy (after subtraction of the value at 0 Gy).
The tumour response was evaluated at the time of maximal
tumour regression on the basis of the change in the maximal
tumour area shown by diagnostic imaging and was classified
as complete response (CR), partial response (PR: >50%
regression), minor response (MR: <50, .25% regression)
or no response (NR: <25% regression). The MN frequency
was higher in the eight tumours showing CR or PR than in
the nine tumours showing MR or NR [MN/BNC (2 Gy-0
Gy); 0.23 ± 0.07 vs 0.11 ± 0.03, P<0.00I].
Fuge 4 Correlation between the NNDT and time to relapse in
six patients who developed recurrence and 13 patients with recur-
























Fie 5 Tumour response to radiotherapy and micronucleus
frequency at 2 Gy after subtraction of that at 0 Gy. MN/BNC,
mean number of micronuclei per binucleate cell; NR, no res-
ponse; MR, minor response; PR, partial response; CR, complete
response. Bars represent the mean for each group.
In this study, we successfully applied the cytokinesis-block
MN assay to human tumour cells in primary culture. The
chief advantage of this method is that it allows the pro-
liferative activity (DF and NNDT) and radiosensitivity (MN
frequency) of tumours to be evaluated in a single series of
assays, something that is impossible with the other methods
currently available. Although the tumours investigated in this
study were heterogeneous and the correlation of the assay
data with treatment outcome needs to be examined further in
specific types of tumours, the results shown in Figures 3-5
suggest the potential clinical usefulness of our assay.
The DF could be determined from the plateau value of the
MNC percentage. If the cells proliferating in vivo (both
clonogenic and non-clonogenic cells) are assumed to be more
likely to undergo in vitro mitosis than the non-proliferating
cells in vivo, this would explain why the percentage of MNCs
reached a plateau. The DF values obtained in this study
approximately agree with the reported proliferative indices of
other human tumours measured using immunohistochemical
methods (Gatter et al., 1986; Garcia et al., 1989), suggesting
that investigation of the correlation between DF and the
growth fraction is warranted. The DF was clearly higher in
the more malignant tumours, and patients with tumours with
a high DF had a worse prognosis. Thus, the DF appears to
be a good index of degree of malignancy.
In this study, NNDT was used as an estimate of the Tpol.
The conditions under which the NNDT represents the Tpot
have been discussed previously (Shibamoto & Streffer, 1991).
Estimation of NNDT is more accurate for tumours in which
the nuclear ratio exceeds 2.0, but this was the case in only six
out of the 58 evaluable tumours. This may have been mainly
because of environmental changes and poor adaptation of
the tumour cells to culture as well as because of the suppres-
sion of nuclear division by cytochalasin B. When the nuclear
ratio does not increase, the estimated NNDT will tend to be
higher than the Tpt. When compared with Tpot data obtained
by the BrdU flow cytometry technique, our NNDT values
agreed well for meningioma (Riccardi et al., 1988) and lung
cancer (Wilson et al., 1988), but were slightly higher for head
and neck cancer (Wilson et al., 1988; Begg et al., 1990) and
bladder cancer (Begg et al., 1988). In clinical radiotherapy,
however, it is most important to detect the tumours with a
short Tpot for which accelerated fractionation may be
indicated, and the NNDT appears to be useful for this
purpose. In addition, Figure 4 indicates that NNDT
measurement is also useful in estimating post-treatment
period with a high risk of recurrence. In countries such as
Japan where BrdU cannot be legally given to patients, our
method could provide a substitute for the BrdU method.
The production of micronuclei is considered to be linked
to cell death (Joshi et al., 1982; Campbell & Warenius, 1989)
and a correlation has been reported between the MN fre-
quency and cell survival for specific cell lines (van Beuningen
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When the MN frequency and cell survival were compared
among various tumour cell lines, only a few cell lines did not
show a correlation (Wandl et al., 1989; Shibamoto et al.,
1991). In such cases, the best parameter of radiation response
is unknown. It may be argued that the MN frequency for all
BNCs does not represent the radiosensitivity of a small pro-
portion of clonogenic cells and hence may not predict the
radiocurability of tumours. However, a correlation appeared
to exist between the MN frequency after irradiation and the
tumour response to radiotherapy in our 17 patients with
measurable lesions. Further investigation in a larger group of
patients and assessment of the correlation with local tumour
control is now in progress.
As a predictive assay, our method has some advantages.
Firstly, the influence of contamination by normal cells can be
excluded. We distinguished tumour cells from normal cells
under the microscope on the basis of morphological criteria
(Papanicolaou, 1954; Barker & Sanford, 1970). Although we
used the central parts of the tumours for assay, normal cells
appeared to be present in all of the specimens in varying
proportions, and it was common for more than half of the
cells to be non-tumour cells. In this respect, our assay is
superior to other assays in which the inability to make such a
distinction can lead to erroneous results.
The relative rapidity of our method when compared with
clonogenic assays is also an advantage. In the case of malig-
nant tumours, most of the important information was
available within 5 days, which should allow the use of our
method as a predictive assay in the clinical setting.
The main disadvantage of this assay is that a relatively
large volume of tumour tissue is required (preferably
> 300 mg). Therefore, a biopsy specinen is likely to be too
small. For this reason, malignant brain tumours are a good
possibility for further studies because most of them are
irradiated after partial resection. Tumours which generally
require post-operative radiation therapy would also be
suitable for further investigation.
In summary, the cytokinesis-block MN assay can be used
for human tumours and simultaneously provides data on the
DF, NNDT and MN frequency. These parameters appear to
be correlated with the treatment outcome of the patients.
Further investigation of the assay seems to be fruitful.
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